Skip to main content
. 2020 Oct 7;48(1):3–13. doi: 10.1111/1346-8138.15605

Figure 2.

Figure 2

Achievement of Hidradenitis Suppurativa Clinical Response (HiSCR) among patients (a) treated with weekly adalimumab (ADA) 40 mg through 52 weeks (b) treated with weekly ADA 40 mg from 64 through 124 weeks and (c) who switched to ADA 80 mg every other week. Missing data were handled using (a,c) the non‐responder imputation (NRI) method or (b) data are shown as observed cases (OC). CI, confidence interval.